Edition:
United States

Neurosearch A/S (NEUR.CO)

NEUR.CO on Copenhagen Stock Exchange

3.06DKK
19 Apr 2018
Change (% chg)

kr.0.24 (+8.51%)
Prev Close
kr.2.82
Open
kr.2.92
Day's High
kr.3.25
Day's Low
kr.2.90
Volume
143,280
Avg. Vol
55,009
52-wk High
kr.5.20
52-wk Low
kr.2.80

Chart for

About

Neurosearch A/S (NEUR) is Denmark-based biopharmaceutical company. It specializes in the research, development and sale of drug candidates. The Company’s portfolio comprises three products: Tesofensine, a drug used in obesity, which works as a monoamine reuptake inhibitor (MRI); Seridopidine, which is applied in central nervous... (more)
No analyst recommendations are available for .

Overall

Beta: 0.15
Market Cap(Mil.): kr.69.24
Shares Outstanding(Mil.): 24.55
Dividend: --
Yield (%): --

Financials

  NEUR.CO Industry Sector
P/E (TTM): -- 200.91 33.50
EPS (TTM): -0.44 -- --
ROI: -14.99 -0.75 13.17
ROE: -14.99 -2.86 14.98

BRIEF-Neurosearch Says Is Investigating Potential Sale Of Company

* SAYS IS IN DISCUSSIONS WITH REGARD TO POTENTIAL SALE OF ITS RIGHTS TO PRIDOPIDINE FOR A SMALL SEVEN FIGURE AMOUNT IN DKK

Apr 19 2018

BRIEF-Neurosearch A/S FY Operating Loss Down to Dkk ‍1.0​ Million

* FY OPERATING LOSS DKK ‍1.0​ MILLION VERSUS LOSS DKK 6.3 MILLION YEAR AGO

Feb 09 2018

BRIEF-Neurosearch Contemplates Divestiture Of The Company

* ‍IS NOW AT A STAGE OF ITS RESOLUTION PLAN AT WHICH IT INTENDS TO EXPLORE POSSIBILITY OF DIVESTING COMPANY DURING COMING MONTHS​

Dec 05 2017

BRIEF-NeuroSearch upgrades its guidance for 2017

* ‍UPGRADES 2017 GUIDANCE FROM AN OPERATING LOSS OF DKK 2.3-3.3 MILLION TO AN OPERATION LOSS OF ABOUT DKK 1 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 17 2017

Earnings vs. Estimates

No consensus analysis data available.